• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.

    8/14/25 4:21:34 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALDX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 13)


    Aldeyra Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    01438T106

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    01438T106


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,051,631.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,051,631.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,051,631.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    01438T106


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,051,631.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,051,631.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,051,631.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    01438T106


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,051,631.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,051,631.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,051,631.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Aldeyra Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    131 Hartwell Avenue, Suite 320,Lexington, MA 02421
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.001 per share (the "Common Stock") of Aldeyra Therapeutics, Inc. ("the Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    01438T106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 59,895,588 outstanding shares of Common Stock as of August 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2025. The Master Fund directly holds 4,051,631 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.
    (b)Percent of class:

    Perceptive Advisors: 6.8% Mr. Edelman: 6.8% Master Fund, Ltd: 6.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 4,051,631 Mr. Edelman: 4,051,631 Master Fund: 4,051,631

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 4,051,631 Mr. Edelman: 4,051,631 Master Fund: 4,051,631

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:08/14/2025
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:08/14/2025
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:08/14/2025
    Get the next $ALDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALDX

    DatePrice TargetRatingAnalyst
    4/3/2024$10.00Perform → Outperform
    Oppenheimer
    4/2/2024$10.00Buy
    H.C. Wainwright
    4/27/2022$15.00Buy
    H.C. Wainwright
    12/21/2021$25.00 → $21.00Buy
    Citigroup
    12/21/2021$24.00 → $15.00Outperform
    SVB Leerink
    More analyst ratings

    $ALDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aldeyra Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Aldeyra Therapeutics from Perform to Outperform and set a new price target of $10.00

    4/3/24 7:39:55 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Aldeyra Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $10.00

    4/2/24 8:09:59 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Aldeyra Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $15.00

    4/27/22 7:14:02 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Financial Officer Alfieri Michael bought $13,250 worth of shares (2,500 units at $5.30) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    8/15/25 4:09:59 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Miller-Rich Nancy bought $10,447 worth of shares (922 units at $11.33) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    10/21/24 8:22:37 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perceptive Advisors Llc bought $833,867 worth of shares (177,993 units at $4.68) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    4/8/24 5:32:55 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmentosa affects more than one million people worldwide. "Although retinitis pigmentosa is a relentlessly progressive condition that has been recognized for decades as a significant cause of blindness, there are no approved therapies for

    8/19/25 7:01:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Dr. Brady's conversation with Matthew Caufield, Director, Equity Research at H.C. Wainwright & Co., is scheduled to begin at 10:30 a.m. ET Wednesday, August 13, 2025. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following

    8/6/25 7:01:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection) for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa. There are currently no approved drug treatments for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmentosa affects more than one million people worldwide and remains a significant cause of inherited blindness. "Retinitis pigmentosa is a serious and incurable sight-threatenin

    7/24/25 7:00:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    SEC Filings

    View All

    Aldeyra Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

    8/19/25 7:00:27 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.

    SCHEDULE 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    8/14/25 4:21:34 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Aldeyra Therapeutics Inc.

    10-Q - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

    8/7/25 4:03:13 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Financial Officer Alfieri Michael bought $13,250 worth of shares (2,500 units at $5.30) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    8/15/25 4:09:59 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Machatha Stephen sold $113,713 worth of shares (22,073 units at $5.15), decreasing direct ownership by 9% to 221,799 units (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    8/13/25 6:03:44 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Walker Neal

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    6/12/25 4:36:38 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Financials

    Live finance-specific insights

    View All

    Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

    In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatment Arms, Potentially Address FDA Feedback following the Prior NDA Review New Drug Application Resubmission Is Anticipated Mid‑2025 A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be Submitted to the Planned NDA Resubmission as Supportive Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechno

    5/5/25 6:34:00 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Reproxalap Reproxalap is an investigational new drug candidate in development for the

    5/5/25 4:00:00 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

    Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were id

    4/3/25 8:00:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Leadership Updates

    Live Leadership Updates

    View All

    Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the

    4/17/25 7:00:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc.

    SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    11/14/24 4:50:29 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc. (Amendment)

    SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    2/14/24 4:52:01 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aldeyra Therapeutics Inc.

    SC 13G - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    2/13/24 4:58:48 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care